CLINICAL STUDY OF VAMANA AND VIRECHANA KARMA (Bio purification) IN THE MANAGEMENT OF HYPOTHYROIDISM

A COMPARATIVE CLINICAL STUDY OF VAMANA AND VIRECHANA KARMA ALONG WITH SHAMANA THERAPY IN THE MANAGEMENT OF HYPOTHYROIDISM

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/07/006060

Enrollment

Registered

2015-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- â?¢ Weight gain â?¢ Puffiness of face & eyelids â?¢ Bilateral peripheral oedema â?¢ Dry &coarse skin â?¢ Breathlessness â?¢ Cold intolerance â?¢ Constipation â?¢ Fatigue â?¢ Muscle ache Health Condition 2: E039- Hypothyroidism, unspecified

Interventions

Intervention1: Virechana Karma followed by Shamana Drugs: Group B-first we will give single virechana after 3g.Panchkola b.i.d with Luke warm water after meals and 2 tab. kaishor guggulu b.i.d with 20

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of hypothyroidism on the basis of Sr. TSH, T3 and T4 levels.

Exclusion criteria

Exclusion criteria: • Ischemic heart diseases • Uncontrolled hypertension • Myocardial Infarction • Cerebrovascular event • Cardiac arrhythmias • Pregnancy • Active malignant disease

Design outcomes

Primary

Measure	Time frame
To bring back the S.T3 S.T4 and S.TSH to the normal levelTimepoint: after 6-8 weeks of intervention	—

Secondary

Measure	Time frame
Patients will be reviewed for sign and symptoms and health condition after 7 day for a period of 4 weeks.Timepoint: after 7th day for a period of 4 weeks.	—

Countries

India

Contacts

Public ContactDr Anup B Thakar

IPGT&RA GAU Jamnagar

mridul2003@gmail.com919460265826

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026